Switch to:
Also traded in: Argentina, Austria, Brazil, Chile, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt N/A
NYSE:JNJ's Cash-to-Debt is ranked lower than
56% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.05 vs. NYSE:JNJ: N/A )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:JNJ' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.15  Med: 1.36 Max: N/A
Current: N/A
Equity-to-Asset 0.49
NYSE:JNJ's Equity-to-Asset is ranked lower than
70% of the 731 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. NYSE:JNJ: 0.49 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:JNJ' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.44  Med: 0.54 Max: 0.67
Current: 0.49
0.44
0.67
Interest Coverage 30.00
NYSE:JNJ's Interest Coverage is ranked lower than
62% of the 632 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 112.31 vs. NYSE:JNJ: 30.00 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:JNJ' s Interest Coverage Range Over the Past 10 Years
Min: 28.29  Med: 35.45 Max: 46.15
Current: 30
28.29
46.15
Piotroski F-Score: 6
Altman Z-Score: 5.30
Beneish M-Score: -2.51
WACC vs ROIC
6.12%
29.71%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 29.03
NYSE:JNJ's Operating Margin % is ranked higher than
92% of the 758 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.95 vs. NYSE:JNJ: 29.03 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:JNJ' s Operating Margin % Range Over the Past 10 Years
Min: 22.36  Med: 25.48 Max: 29.44
Current: 29.03
22.36
29.44
Net Margin % 22.52
NYSE:JNJ's Net Margin % is ranked higher than
89% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.06 vs. NYSE:JNJ: 22.52 )
Ranked among companies with meaningful Net Margin % only.
NYSE:JNJ' s Net Margin % Range Over the Past 10 Years
Min: 14.87  Med: 20.07 Max: 23.01
Current: 22.52
14.87
23.01
ROE % 22.77
NYSE:JNJ's ROE % is ranked higher than
86% of the 780 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.91 vs. NYSE:JNJ: 22.77 )
Ranked among companies with meaningful ROE % only.
NYSE:JNJ' s ROE % Range Over the Past 10 Years
Min: 17.02  Med: 23.04 Max: 30.17
Current: 22.77
17.02
30.17
ROA % 11.63
NYSE:JNJ's ROA % is ranked higher than
82% of the 805 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.71 vs. NYSE:JNJ: 11.63 )
Ranked among companies with meaningful ROA % only.
NYSE:JNJ' s ROA % Range Over the Past 10 Years
Min: 8.93  Med: 12.22 Max: 15.61
Current: 11.63
8.93
15.61
ROC (Joel Greenblatt) % 109.72
NYSE:JNJ's ROC (Joel Greenblatt) % is ranked higher than
94% of the 793 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.48 vs. NYSE:JNJ: 109.72 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:JNJ' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 65.66  Med: 87.89 Max: 119.25
Current: 109.72
65.66
119.25
3-Year Revenue Growth Rate 1.30
NYSE:JNJ's 3-Year Revenue Growth Rate is ranked lower than
64% of the 634 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. NYSE:JNJ: 1.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:JNJ' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 1.3  Med: 9.5 Max: 14
Current: 1.3
1.3
14
3-Year EBITDA Growth Rate 7.70
NYSE:JNJ's 3-Year EBITDA Growth Rate is ranked lower than
52% of the 601 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.90 vs. NYSE:JNJ: 7.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:JNJ' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -6.6  Med: 11.3 Max: 24.1
Current: 7.7
-6.6
24.1
3-Year EPS without NRI Growth Rate 7.20
NYSE:JNJ's 3-Year EPS without NRI Growth Rate is ranked lower than
51% of the 576 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.60 vs. NYSE:JNJ: 7.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NYSE:JNJ' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -8.6  Med: 12.4 Max: 34.2
Current: 7.2
-8.6
34.2
GuruFocus has detected 6 Warning Signs with Johnson & Johnson $NYSE:JNJ.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:JNJ's 30-Y Financials

Financials (Next Earnings Date: 2017-10-18 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

JNJ Guru Trades in Q3 2016

Eaton Vance Worldwide Health Sciences Fund 450,936 sh (New)
Joel Greenblatt 214,043 sh (+4262.88%)
Jim Simons 1,475,100 sh (+135.60%)
Paul Tudor Jones 28,124 sh (+80.83%)
Diamond Hill Capital 2,296 sh (+8.82%)
Pioneer Investments 3,454,669 sh (+7.16%)
John Rogers 858,549 sh (+0.11%)
Ken Fisher 10,845,620 sh (unchged)
Warren Buffett 327,100 sh (unchged)
Tom Gayner 610,800 sh (unchged)
Prem Watsa 82,850 sh (unchged)
John Hussman 25,000 sh (unchged)
David Rolfe 5,250 sh (unchged)
David Carlson 460,000 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Tom Russo Sold Out
Richard Perry Sold Out
Richard Snow 3,215 sh (-0.16%)
Dodge & Cox 34,985 sh (-0.57%)
T Rowe Price Equity Income Fund 3,380,000 sh (-0.59%)
Jeff Auxier 104,176 sh (-0.90%)
Mairs and Power 2,153,237 sh (-1.49%)
John Buckingham 62,429 sh (-2.27%)
Charles Brandes 126,627 sh (-4.88%)
Mario Gabelli 294,127 sh (-5.98%)
Murray Stahl 28,648 sh (-6.45%)
Barrow, Hanley, Mewhinney & Strauss 12,334,416 sh (-6.63%)
Lee Ainslie 26,320 sh (-6.77%)
Tweedy Browne 2,978,783 sh (-7.39%)
Yacktman Focused Fund 1,800,000 sh (-7.69%)
Donald Yacktman 6,143,753 sh (-7.91%)
Manning & Napier Advisors, Inc 3,028,532 sh (-8.17%)
Richard Pzena 1,002,314 sh (-9.13%)
Sarah Ketterer 705,335 sh (-10.40%)
PRIMECAP Management 2,519,397 sh (-11.00%)
Yacktman Fund 3,200,000 sh (-11.11%)
Louis Moore Bacon 2,875 sh (-19.06%)
Michael Price 20,000 sh (-20.00%)
Jeremy Grantham 7,282,964 sh (-25.24%)
Robert Olstein 30,000 sh (-26.83%)
Jim Chanos 35,387 sh (-29.00%)
Ruane Cunniff 5,713 sh (-55.83%)
Ray Dalio 44,400 sh (-65.77%)
John Paulson 35,000 sh (-72.66%)
First Eagle Investment 28,177 sh (-96.29%)
» More
Q4 2016

JNJ Guru Trades in Q4 2016

Steven Cohen 245,700 sh (New)
Jim Simons 3,423,100 sh (+132.06%)
Joel Greenblatt 475,722 sh (+122.26%)
Prem Watsa 151,250 sh (+82.56%)
Pioneer Investments 4,830,327 sh (+39.82%)
Sarah Ketterer 769,679 sh (+9.12%)
Lee Ainslie 28,530 sh (+8.40%)
Charles Brandes 131,352 sh (+3.73%)
John Rogers 870,359 sh (+1.38%)
Diamond Hill Capital 2,327 sh (+1.35%)
Ken Fisher 10,957,134 sh (+1.03%)
John Buckingham 62,716 sh (+0.46%)
Warren Buffett 327,100 sh (unchged)
Michael Price 20,000 sh (unchged)
Tom Gayner 610,800 sh (unchged)
Yacktman Focused Fund 1,800,000 sh (unchged)
Yacktman Fund 3,200,000 sh (unchged)
Richard Snow 3,215 sh (unchged)
David Rolfe 5,250 sh (unchged)
David Carlson 460,000 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 450,936 sh (unchged)
John Paulson Sold Out
John Hussman Sold Out
Ray Dalio Sold Out
Jim Chanos Sold Out
Jeff Auxier 104,076 sh (-0.10%)
T Rowe Price Equity Income Fund 3,370,000 sh (-0.30%)
Richard Pzena 998,964 sh (-0.33%)
Mairs and Power 2,143,539 sh (-0.45%)
First Eagle Investment 28,031 sh (-0.52%)
Donald Yacktman 6,035,969 sh (-1.75%)
Dodge & Cox 34,185 sh (-2.29%)
Manning & Napier Advisors, Inc 2,942,895 sh (-2.83%)
Robert Olstein 29,000 sh (-3.33%)
Barrow, Hanley, Mewhinney & Strauss 11,875,386 sh (-3.72%)
Murray Stahl 26,905 sh (-6.08%)
Ruane Cunniff 5,238 sh (-8.31%)
Mario Gabelli 257,586 sh (-12.42%)
PRIMECAP Management 2,171,097 sh (-13.82%)
Tweedy Browne 2,386,562 sh (-19.88%)
Jeremy Grantham 5,255,334 sh (-27.84%)
Paul Tudor Jones 5,800 sh (-79.38%)
» More
Q1 2017

JNJ Guru Trades in Q1 2017

Jim Simons 7,102,700 sh (+107.49%)
Paul Tudor Jones 11,807 sh (+103.57%)
Barrow, Hanley, Mewhinney & Strauss 12,700,845 sh (+6.95%)
Mairs and Power 2,227,380 sh (+3.91%)
T Rowe Price Equity Income Fund 3,500,000 sh (+3.86%)
John Rogers 892,116 sh (+2.50%)
John Buckingham 63,690 sh (+1.55%)
Ken Fisher 11,093,898 sh (+1.25%)
Mario Gabelli 260,455 sh (+1.11%)
Charles Brandes 132,387 sh (+0.79%)
Warren Buffett 327,100 sh (unchged)
Robert Olstein 29,000 sh (unchged)
Tom Gayner 610,800 sh (unchged)
Prem Watsa 151,250 sh (unchged)
Yacktman Fund 3,200,000 sh (unchged)
Richard Snow 3,215 sh (unchged)
David Rolfe 5,250 sh (unchged)
David Carlson 460,000 sh (unchged)
Tweedy Browne Global Value 865,835 sh (unchged)
Sarah Ketterer Sold Out
Steven Cohen Sold Out
Louis Moore Bacon Sold Out
Jeff Auxier 103,426 sh (-0.62%)
Tweedy Browne 2,368,267 sh (-0.77%)
Diamond Hill Capital 2,308 sh (-0.82%)
Donald Yacktman 5,919,270 sh (-1.93%)
Dodge & Cox 33,374 sh (-2.37%)
First Eagle Investment 26,921 sh (-3.96%)
Yacktman Focused Fund 1,700,000 sh (-5.56%)
Jeremy Grantham 4,919,730 sh (-6.39%)
Richard Pzena 914,439 sh (-8.46%)
Murray Stahl 24,319 sh (-9.61%)
Lee Ainslie 23,120 sh (-18.96%)
Ruane Cunniff 4,240 sh (-19.05%)
Manning & Napier Advisors, Inc 1,933,205 sh (-34.31%)
Joel Greenblatt 291,296 sh (-38.77%)
Pioneer Investments 2,210,407 sh (-54.24%)
PRIMECAP Management 949,075 sh (-56.29%)
Michael Price 5,000 sh (-75.00%)
Eaton Vance Worldwide Health Sciences Fund 347,253 sh (-22.99%)
» More
Q2 2017

JNJ Guru Trades in Q2 2017

Ken Fisher 11,499,415 sh (+3.66%)
Tweedy Browne Global Value 865,835 sh (unchged)
T Rowe Price Equity Income Fund 3,495,600 sh (-0.13%)
Yacktman Fund 3,100,000 sh (-3.13%)
Manning & Napier Advisors, Inc 1,832,479 sh (-5.21%)
Yacktman Focused Fund 1,600,000 sh (-5.88%)
» More
» Details

Insider Trades

Latest Guru Trades with JNJ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:NYSE:PFE, NYSE:MRK, NYSE:ABBV, NYSE:LLY, NYSE:BMY, NAS:AERI, AMEX:TXMD, NAS:RTRX, NAS:RMTI, NAS:ZGNX, AMEX:NNVC, NAS:ALIM, NAS:PRPH, NAS:TNXP, NAS:IMNP, AMEX:AXN, OTCPK:INNV, NAS:ALQA, OTCPK:INBP, OTCPK:ECTE » details
Traded in other countries:JNJ.Argentina, JNJ.Austria, JNJB34.Brazil, JNJ.Chile, JNJ.Germany, JNJ.Mexico, JNJ.Switzerland, 0R34.UK,
Headquarter Location:USA
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of products in the health care field within its Consumer, Pharmaceutical and Medical Devices segments.

Johnson & Johnson is the world's largest and most diverse healthcare company. Three divisions make up the company: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. About half of total revenue is generated within the United States.

Guru Investment Theses on Johnson & Johnson

Ariel Funds Comments on Johnson & Johnson - Sep 28, 2016

Medical giant Johnson & Johnson (NYSE:JNJ) rallied +12.66%, due to a strong earnings report. In April the company beat analysts’ estimates and also raised guidance for the year. Earnings were driven by strong sales of drugs like Stelara and Xarelto. At this point pharmaceuticals are the company’s largest business division—ahead of powerhouses such as medical devices and consumer health products. We think the trajectory of the business continues to point upward.



From John Rogers (Trades, Portfolio)' second quarter 2016 Ariel Global Fund commentary.

Check out John Rogers latest stock trades

Yacktman Funds Comments on Johnson & Johnson - Aug 05, 2016

JNJ (NYSE:JNJ) performed well in the second quarter after delivering solid results. Few companies have the financial strength and product diversity of JNJ, which is why it is one of only two companies in the United States (Microsoft is the other) that commands a triple-A credit rating. We think JNJ can deliver solid growth and strong free cash flow over time.



From Yacktman Focused Fund (Trades, Portfolio) second quarter 2016 commentary.


Check out Donald Yacktman,Yacktman Focused Fund latest stock trades

Charles Brandes Comments on Johnson & Johnson - Oct 21, 2015

Healthcare giant Johnson & Johnson (NYSE:JNJ), which has diverse operations in pharmaceuticals, medical devices, biotechnology and consumer health, has faced potential competition in its pharmaceutical segment and lingering concerns over product recalls and manufacturing issues in its consumer segment. Nonetheless, we believe the company’s fundamentals remain attractive, including its strong competitive position and balance sheet, as well as a history of prudent capital deployment. The company generates approximately 70% of its revenues from businesses which command a #1 or #2 global market share, and 25% from products launched over the last five years. Speaking to the strength of its balance sheet, Johnson & Johnson is one of only four U.S. industrial companies with a AAA credit rating from both S&P and Moody’s.

From Charles Brandes (Trades, Portfolio)' third quarter 2015 commentary, Volatility: Misbehaving—In Action.

Check out Charles Brandes latest stock trades

Top Ranked Articles about Johnson & Johnson

Large-Cap Indexes Lower, Nasdaq Reaches New High Nasdaq closes at 6410.81
U.S. large-cap indexes were mostly lower on Monday while technology stocks gained and the Nasdaq reached a new high. For the day, the Dow Jones Industrial Average closed at 21513.17 for a loss of -66.90 points or -0.31%. The S&P 500 closed at 2469.91 for a loss of -2.63 points or -0.11%. The Nasdaq Composite closed at 6410.81 for a gain of 23.05 points or 0.36%. The VIX Volatility Index was higher for the day at 9.42 for a gain of 0.06 points or 0.64%. Read more...
An Excellent Quarter From This Explosive Tech Giant Analyzing Microsoft's 4th-quarter earnings report
(Published by Nick McCullum on July 24) Read more...
US Market Indexes Lower on Friday Dow Jones closes at 21580.07
U.S. market indexes were lower on Friday. Read more...
Growth Investing in a Sophisticated Market The ability to grow over time is a key element in every investment
Most investors will agree with the assumption that the concept of growth investing is alien to day traders. Read more...
Yacktman Focused Fund Buys Cognizant and Infosys, Sells Out of Unilever The fund's largest 2nd-quarter trades
The Yacktman Focused Fund (Trades, Portfolio) manages a portfolio composed of 20 stocks with a total value of $3,286 million. It seeks long-term capital appreciation and current income. During the second quarter, the guru traded shares in the following stocks: Read more...
Yacktman Focused Fund Divests Unilever in 2nd Quarter Guru sells outweigh the buys
The Yacktman Focused Fund (Trades, Portfolio) primarily seeks long-term capital appreciation and current income. During the second quarter, the fund's managers, Stephen Yacktman and Jason Subotky, eliminated their Unilever NV (NYSE:UN) position and trimmed several other positions, including Samsung Electronics Co. Ltd. (XKRX:005935), Oracle Corp. (NYSE:ORCL) and Johnson & Johnson (NYSE:JNJ). Read more...
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2017
Johnson & Johnson Releases 2016 Health for Humanity Report
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
Douglas Wallace, Ph.D., Wins 2017 Dr. Paul Janssen Award for Biomedical Research

Ratios

vs
industry
vs
history
PE Ratio 22.47
JNJ's PE Ratio is ranked higher than
62% of the 555 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.93 vs. JNJ: 22.47 )
Ranked among companies with meaningful PE Ratio only.
JNJ' s PE Ratio Range Over the Past 10 Years
Min: 10.5  Med: 17.83 Max: 24
Current: 22.47
10.5
24
Forward PE Ratio 19.01
JNJ's Forward PE Ratio is ranked higher than
52% of the 67 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.90 vs. JNJ: 19.01 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 22.47
JNJ's PE Ratio without NRI is ranked higher than
62% of the 554 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.21 vs. JNJ: 22.47 )
Ranked among companies with meaningful PE Ratio without NRI only.
JNJ' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.5  Med: 17.83 Max: 24
Current: 22.47
10.5
24
Price-to-Owner-Earnings 22.73
JNJ's Price-to-Owner-Earnings is ranked higher than
68% of the 303 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.90 vs. JNJ: 22.73 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
JNJ' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.94  Med: 17.35 Max: 27.78
Current: 22.73
10.94
27.78
PB Ratio 5.13
JNJ's PB Ratio is ranked lower than
76% of the 751 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. JNJ: 5.13 )
Ranked among companies with meaningful PB Ratio only.
JNJ' s PB Ratio Range Over the Past 10 Years
Min: 2.68  Med: 3.72 Max: 5.26
Current: 5.13
2.68
5.26
PS Ratio 5.11
JNJ's PS Ratio is ranked lower than
67% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.97 vs. JNJ: 5.11 )
Ranked among companies with meaningful PS Ratio only.
JNJ' s PS Ratio Range Over the Past 10 Years
Min: 2.16  Med: 3.22 Max: 5.25
Current: 5.11
2.16
5.25
Price-to-Free-Cash-Flow 22.03
JNJ's Price-to-Free-Cash-Flow is ranked higher than
57% of the 208 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.89 vs. JNJ: 22.03 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
JNJ' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 10.29  Med: 16.63 Max: 24.34
Current: 22.03
10.29
24.34
Price-to-Operating-Cash-Flow 18.54
JNJ's Price-to-Operating-Cash-Flow is ranked higher than
51% of the 277 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.02 vs. JNJ: 18.54 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
JNJ' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.99  Med: 13.04 Max: 19.53
Current: 18.54
8.99
19.53
EV-to-EBIT 16.55
JNJ's EV-to-EBIT is ranked higher than
62% of the 559 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.11 vs. JNJ: 16.55 )
Ranked among companies with meaningful EV-to-EBIT only.
JNJ' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.8  Med: 13.3 Max: 18.2
Current: 16.55
7.8
18.2
EV-to-EBITDA 14.58
JNJ's EV-to-EBITDA is ranked higher than
60% of the 587 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.50 vs. JNJ: 14.58 )
Ranked among companies with meaningful EV-to-EBITDA only.
JNJ' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.7  Med: 11.2 Max: 15
Current: 14.58
6.7
15
PEG Ratio 2.46
JNJ's PEG Ratio is ranked lower than
58% of the 313 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.94 vs. JNJ: 2.46 )
Ranked among companies with meaningful PEG Ratio only.
JNJ' s PEG Ratio Range Over the Past 10 Years
Min: 1.19  Med: 1.91 Max: 27.59
Current: 2.46
1.19
27.59
Shiller PE Ratio 26.08
JNJ's Shiller PE Ratio is ranked higher than
72% of the 198 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 39.37 vs. JNJ: 26.08 )
Ranked among companies with meaningful Shiller PE Ratio only.
JNJ' s Shiller PE Ratio Range Over the Past 10 Years
Min: 15.57  Med: 21.29 Max: 29.71
Current: 26.08
15.57
29.71
Current Ratio 2.52
JNJ's Current Ratio is ranked higher than
52% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. JNJ: 2.52 )
Ranked among companies with meaningful Current Ratio only.
JNJ' s Current Ratio Range Over the Past 10 Years
Min: 1.2  Med: 1.96 Max: 3.08
Current: 2.52
1.2
3.08
Quick Ratio 2.17
JNJ's Quick Ratio is ranked higher than
56% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.82 vs. JNJ: 2.17 )
Ranked among companies with meaningful Quick Ratio only.
JNJ' s Quick Ratio Range Over the Past 10 Years
Min: 0.94  Med: 1.5 Max: 2.68
Current: 2.17
0.94
2.68
Days Inventory 138.59
JNJ's Days Inventory is ranked lower than
63% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 117.36 vs. JNJ: 138.59 )
Ranked among companies with meaningful Days Inventory only.
JNJ' s Days Inventory Range Over the Past 10 Years
Min: 100.19  Med: 110.33 Max: 138.59
Current: 138.59
100.19
138.59
Days Sales Outstanding 61.90
JNJ's Days Sales Outstanding is ranked higher than
62% of the 651 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.70 vs. JNJ: 61.90 )
Ranked among companies with meaningful Days Sales Outstanding only.
JNJ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.94  Med: 57.41 Max: 61.9
Current: 61.9
53.94
61.9
Days Payable 99.87
JNJ's Days Payable is ranked higher than
69% of the 600 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.96 vs. JNJ: 99.87 )
Ranked among companies with meaningful Days Payable only.
JNJ' s Days Payable Range Over the Past 10 Years
Min: 98.27  Med: 111.33 Max: 147.94
Current: 99.87
98.27
147.94

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.43
JNJ's Dividend Yield % is ranked higher than
73% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.23 vs. JNJ: 2.43 )
Ranked among companies with meaningful Dividend Yield % only.
JNJ' s Dividend Yield % Range Over the Past 10 Years
Min: 2.05  Med: 2.84 Max: 3.84
Current: 2.43
2.05
3.84
Dividend Payout Ratio 0.54
JNJ's Dividend Payout Ratio is ranked lower than
74% of the 406 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.33 vs. JNJ: 0.54 )
Ranked among companies with meaningful Dividend Payout Ratio only.
JNJ' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.39  Med: 0.51 Max: 0.65
Current: 0.54
0.39
0.65
3-Year Dividend Growth Rate 6.70
JNJ's 3-Year Dividend Growth Rate is ranked higher than
50% of the 299 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.90 vs. JNJ: 6.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
JNJ' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 6.7  Med: 13.4 Max: 17.5
Current: 6.7
6.7
17.5
Forward Dividend Yield % 2.48
JNJ's Forward Dividend Yield % is ranked higher than
70% of the 673 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. JNJ: 2.48 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.41
JNJ's 5-Year Yield-on-Cost % is ranked higher than
71% of the 821 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.11 vs. JNJ: 3.41 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
JNJ' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.88  Med: 3.98 Max: 5.39
Current: 3.41
2.88
5.39
3-Year Average Share Buyback Ratio 1.20
JNJ's 3-Year Average Share Buyback Ratio is ranked higher than
94% of the 473 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.10 vs. JNJ: 1.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
JNJ' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4.3  Med: 0.1 Max: 2.3
Current: 1.2
-4.3
2.3

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 22.51
JNJ's Price-to-Tangible-Book is ranked lower than
94% of the 690 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.51 vs. JNJ: 22.51 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
JNJ' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.5  Med: 9.3 Max: 22.51
Current: 22.51
4.5
22.51
Price-to-Intrinsic-Value-Projected-FCF 1.83
JNJ's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
59% of the 328 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. JNJ: 1.83 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
JNJ' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.84  Med: 1.62 Max: 4.4
Current: 1.83
0.84
4.4
Price-to-Intrinsic-Value-DCF (Earnings Based) 2.10
JNJ's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
71% of the 83 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.54 vs. JNJ: 2.10 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.59
JNJ's Price-to-Median-PS-Value is ranked lower than
77% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.09 vs. JNJ: 1.59 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
JNJ' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.49  Med: 1.01 Max: 1.85
Current: 1.59
0.49
1.85
Price-to-Peter-Lynch-Fair-Value 2.51
JNJ's Price-to-Peter-Lynch-Fair-Value is ranked lower than
71% of the 207 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.62 vs. JNJ: 2.51 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
JNJ' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.53  Med: 1.79 Max: 4.72
Current: 2.51
0.53
4.72
Price-to-Graham-Number 4.73
JNJ's Price-to-Graham-Number is ranked lower than
85% of the 480 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.08 vs. JNJ: 4.73 )
Ranked among companies with meaningful Price-to-Graham-Number only.
JNJ' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.67  Med: 2.98 Max: 5.97
Current: 4.73
1.67
5.97
Earnings Yield (Greenblatt) % 6.04
JNJ's Earnings Yield (Greenblatt) % is ranked higher than
74% of the 805 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. JNJ: 6.04 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
JNJ' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 5.5  Med: 7.5 Max: 12.9
Current: 6.04
5.5
12.9
Forward Rate of Return (Yacktman) % 12.70
JNJ's Forward Rate of Return (Yacktman) % is ranked higher than
59% of the 380 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.46 vs. JNJ: 12.70 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
JNJ' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 1.7  Med: 12.9 Max: 18.9
Current: 12.7
1.7
18.9

More Statistics

Revenue (TTM) (Mil) $72,531.00
EPS (TTM) $ 5.92
Beta0.68
Short Percentage of Float0.59%
52-Week Range $109.32 - 137.08
Shares Outstanding (Mil)2,693.83

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 75,892 79,191 82,866
EPS ($) 7.12 7.69 8.16
EPS without NRI ($) 7.12 7.69 8.16
EPS Growth Rate
(Future 3Y To 5Y Estimate)
4.83%
Dividends per Share ($) 3.34 3.55 3.73
» More Articles for NYSE:JNJ

Headlines

Articles On GuruFocus.com
Why 3M Hit an All-Time High Jul 20 2017 
Growth Investing in a Sophisticated Market Jul 20 2017 
Yacktman Focused Fund Divests Unilever in 2nd Quarter Jul 19 2017 
Yacktman Focused Fund Buys Cognizant and Infosys, Sells Out of Unilever Jul 19 2017 
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2017 Jul 17 2017 
Better Dividend Aristocrat: Johnson & Johnson or Medtronic? Jul 13 2017 
TransAlta Renewables: A Safe 5.7% Monthly Dividend Yield Jul 06 2017 
Johnson & Johnson Releases 2016 Health for Humanity Report Jun 22 2017 
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results Jun 20 2017 
Douglas Wallace, Ph.D., Wins 2017 Dr. Paul Janssen Award for Biomedical Research Jun 20 2017 

More From Other Websites
[$$] How Blockbuster Drugs Fight Off Cheaper Competition Jul 24 2017
Samsung Releases Arthritis Drug in First Foray Into U.S. Pharmaceuticals Jul 24 2017
J&J Snack Foods posts 3Q profit Jul 24 2017
Nasdaq hits record, J&J drags Dow Jul 24 2017
US STOCKS-Nasdaq, tech shine as earnings pick up; Dow, S&P lag Jul 24 2017
Chipotle Is Doomed Unless It Takes This One Dramatic Measure Jul 24 2017
US STOCKS SNAPSHOT-J&J weighs on Dow, S&P; Nasdaq hits record Jul 24 2017
There’s a promising new HIV vaccine that can protect against multiple strains at once Jul 24 2017
US STOCKS-Nasdaq hits record ahead of big tech earnings; Dow, S&P lag Jul 24 2017
Merck, Samsung Accelerate a Biosimilar Price War Jul 24 2017
US STOCKS-S&P, Dow lower as J&J drags; Nasdaq hits record Jul 24 2017
Merck, Samsung Bioepis launch discounted U.S. Remicade alternative Jul 24 2017
Impact on health care if Dems pass 'better plan' Jul 24 2017
Merck launches biosimilar version of J&J blockbuster Remicade Jul 24 2017
U.S Stocks Quiet, But One Foreign Group Is Rising Jul 24 2017
2 Ways To Trade This Week's Healthcare Earnings Jul 24 2017
US STOCKS-S&P, Dow lower as Johnson & Johnson drags Jul 24 2017
Johnson & Johnson: Consumer Products in 2Q17 Jul 24 2017
Why Abiomed Expects to Benefit from Impella in Cardiogenic Shock Jul 24 2017
Understanding JNJ’s Latest Stock Price Rise Jul 24 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}